Christer Wornstedt

Title: The Innovations of Christer Wornstedt

Introduction

Christer Wornstedt is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of cancer research through his innovative work on the Smad2 protein. His research focuses on the phosphorylation and interaction of Smad2 with Smad4, which plays a crucial role in cellular signaling pathways.

Latest Patents

Wornstedt holds a patent for "Smad2 phosphorylation and interaction with Smad4." This invention describes the amino acid residues of the Smad2 protein that are essential for its phosphorylation and activity. The patent includes Smad2 polypeptide fragments and biologically functional variants, including dominant-negative variants of Smad2 and related antibodies. Additionally, it covers nucleic acids that encode such variants and antibodies that selectively bind pathway-restricted Smad proteins phosphorylated at the C-terminal tail. The patent also provides methods and products for utilizing these nucleic acids and polypeptides.

Career Highlights

Wornstedt is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research in cancer biology. His work has implications for understanding cancer mechanisms and developing targeted therapies.

Collaborations

Wornstedt has collaborated with esteemed colleagues such as Kiyoshi Tamaki and Ulla Engström, contributing to a rich exchange of ideas and research findings in the field.

Conclusion

Christer Wornstedt's innovative work on the Smad2 protein and its interactions has the potential to impact cancer research significantly. His contributions through patents and collaborations highlight the importance of scientific innovation in addressing complex health challenges.